Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Oxaliplatin 85 mg/m^2
Drug: Oxaliplatin 130 mg/m^2
Drug: Capecitabine 1000 mg/m^2
Drug: Leucovorin 200 mg/m^2
Drug: Fluorouracil 400 mg/m^2
Drug: Bevacizumab 7.5 mg/kg
Drug: Placebo for bevacizumab 7.5 mg/kg
Drug: Placebo for bevacizumab 5 mg/kg
Drug: Bevacizumab 5 mg/kg

First Posted Date: 2003-09-18

Last Posted Date: 2016-10-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2035

Registration Number: NCT00069095

A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Drug: 5 FU
Drug: Oxaliplatin
Drug: capecitabine [Xeloda]
Drug: Leucovorin

First Posted Date: 2003-09-18

Last Posted Date: 2016-04-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 627

Registration Number: NCT00069108

Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes

First Posted Date: 2003-04-01

Last Posted Date: 2016-08-24

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT00057317

Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes

Interventions: Drug: RO 205-2349

First Posted Date: 2003-04-01

Last Posted Date: 2023-04-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 190

Registration Number: NCT00057304

A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: trastuzumab (Herceptin®)
Drug: anastrazole (Arimidex®)

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 208

Registration Number: NCT00022672

Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Herceptin

First Posted Date: 2003-01-27

Last Posted Date: 2017-04-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 5099

Registration Number: NCT00045032

Locations: 🇦🇺
Saint John of God Hospital, Geelong, Australian Capital Territory, Australia
🇦🇹
Landeskrankenhaus Klagenfurt, Klagenfurt, Austria
🇧🇪
Centre Hospitalier Notre Dame - Reine Fabiola, Charleroi, Belgium

and more 200 locations

Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Capecitabine
Drug: Irinotecan

First Posted Date: 2003-01-27

Last Posted Date: 2016-04-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 67

Registration Number: NCT00022698

Locations: 🇺🇸
Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States
🇺🇸
Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States
🇺🇸
George Washington University Medical Center, Washington, District of Columbia, United States

and more 14 locations

Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Phase 3

Completed

Conditions: Chronic Hepatitis B

First Posted Date: 2002-11-14

Last Posted Date: 2017-02-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 820

Registration Number: NCT00048945

A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients

Phase 3

Completed

Conditions: Kidney Transplantation

Interventions: Drug: Corticosteroids
Drug: Neoral
Drug: Zenapax
Drug: mycophenolate mofetil [CellCept]

First Posted Date: 2002-10-25

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 539

Registration Number: NCT00048152

A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

Phase 4

Completed

Conditions: Heart Transplantation

Interventions: Drug: Daclizumab
Drug: Methylprednisolone
Drug: Placebo
Drug: Mycophenolate mofetil
Drug: cyclosporine

First Posted Date: 2002-10-25

Last Posted Date: 2016-06-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 434

Registration Number: NCT00048165

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy